News

Jerusalem, Israel

Last month NovellusDx was granted Israel Patent #239624 For METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS for its Functional Annotation of Cancer Treatment technology. The patent, which will remain in force until 2034, adds to the protection of the company’s FACT sytem, which augments NGS data with information regarding functional significance and response to targeted therapies.